Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Margaret Macy

Concepts (237)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Neuroblastoma
14
2026
174
3.080
 Why?
Antineoplastic Combined Chemotherapy Protocols
15
2026
1969
1.550
 Why?
Neoplasms
19
2026
2913
1.400
 Why?
Central Nervous System Neoplasms
3
2024
177
1.310
 Why?
Neoplasm Recurrence, Local
14
2026
1150
1.220
 Why?
Sarcoma, Ewing
3
2025
103
1.130
 Why?
Cyclin-Dependent Kinase 4
1
2024
53
0.820
 Why?
Protein Kinase Inhibitors
7
2025
981
0.820
 Why?
Cyclin-Dependent Kinase 6
1
2024
49
0.820
 Why?
Central Nervous System Diseases
1
2024
74
0.770
 Why?
Neoplasms, Second Primary
1
2024
102
0.750
 Why?
Glioma
5
2025
429
0.740
 Why?
Antineoplastic Agents
12
2026
2219
0.730
 Why?
Drug Resistance, Neoplasm
8
2026
883
0.720
 Why?
Piperazines
1
2024
375
0.700
 Why?
Antibodies, Monoclonal, Humanized
5
2022
992
0.690
 Why?
Glycolipids
1
2021
53
0.670
 Why?
Child
45
2026
22739
0.620
 Why?
Pyridines
1
2024
609
0.620
 Why?
Radiation Injuries
2
2019
149
0.610
 Why?
Indazoles
2
2022
85
0.590
 Why?
Bevacizumab
2
2019
168
0.580
 Why?
Brain Stem Neoplasms
2
2017
87
0.570
 Why?
Benzamides
2
2022
226
0.560
 Why?
Astrocytoma
2
2017
130
0.560
 Why?
Radiotherapy
1
2019
206
0.550
 Why?
Child, Preschool
28
2026
11868
0.550
 Why?
Chemoradiotherapy
2
2017
239
0.540
 Why?
Brain Diseases
1
2019
155
0.540
 Why?
Receptor Protein-Tyrosine Kinases
2
2022
231
0.530
 Why?
Angiogenesis Inhibitors
1
2019
239
0.520
 Why?
Adolescent
33
2026
22573
0.470
 Why?
3-Iodobenzylguanidine
3
2025
13
0.460
 Why?
Prognosis
14
2026
4329
0.450
 Why?
Gangliosides
2
2025
23
0.410
 Why?
Granulocyte-Macrophage Colony-Stimulating Factor
2
2026
161
0.390
 Why?
Brain Neoplasms
5
2022
1331
0.390
 Why?
Sarcoma
2
2015
207
0.390
 Why?
Bridged Bicyclo Compounds, Heterocyclic
2
2026
280
0.390
 Why?
Rhabdomyosarcoma
2
2025
65
0.350
 Why?
Sulfonamides
2
2026
583
0.340
 Why?
Piperidines
2
2025
222
0.340
 Why?
Quinazolines
2
2023
266
0.330
 Why?
Neoplasms, Germ Cell and Embryonal
1
2012
76
0.330
 Why?
Topoisomerase II Inhibitors
1
2010
24
0.320
 Why?
Antineoplastic Agents, Immunological
2
2025
198
0.320
 Why?
Biomarkers, Tumor
4
2022
1329
0.320
 Why?
Humans
53
2026
145763
0.320
 Why?
Maximum Tolerated Dose
6
2025
211
0.310
 Why?
Follow-Up Studies
10
2026
5428
0.310
 Why?
Survival Rate
8
2026
2094
0.300
 Why?
Antibodies, Monoclonal
7
2026
1505
0.290
 Why?
Glioblastoma
1
2012
354
0.280
 Why?
Young Adult
15
2026
14251
0.270
 Why?
Leukemia
1
2010
246
0.270
 Why?
DNA Damage
1
2010
437
0.260
 Why?
Male
31
2026
73003
0.250
 Why?
Infant
14
2026
10090
0.250
 Why?
Female
31
2026
79035
0.240
 Why?
Leukemia, Myeloid, Acute
3
2025
688
0.230
 Why?
Trastuzumab
1
2026
118
0.230
 Why?
Medical Oncology
2
2024
340
0.230
 Why?
Liver Neoplasms
1
2012
777
0.220
 Why?
Infratentorial Neoplasms
1
2026
71
0.220
 Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
2020
297
0.220
 Why?
Gene Expression Profiling
1
2012
1777
0.220
 Why?
Camptothecin
2
2017
138
0.220
 Why?
Cyclin D
1
2024
8
0.220
 Why?
Cyclin-Dependent Kinases
1
2025
122
0.210
 Why?
Glycogen Synthase Kinase 3 beta
1
2024
74
0.210
 Why?
Ependymoma
1
2026
176
0.200
 Why?
Dose-Response Relationship, Drug
5
2025
2028
0.200
 Why?
TOR Serine-Threonine Kinases
3
2024
456
0.200
 Why?
Neoplasm Staging
3
2024
1474
0.200
 Why?
Bone Neoplasms
2
2024
265
0.200
 Why?
Carcinoma, Non-Small-Cell Lung
2
2023
1191
0.200
 Why?
Sirolimus
2
2016
282
0.190
 Why?
Oncogene Proteins, Fusion
1
2024
212
0.180
 Why?
Osteosarcoma
1
2023
89
0.180
 Why?
High-Throughput Nucleotide Sequencing
2
2023
534
0.180
 Why?
Pediatrics
2
2020
1125
0.180
 Why?
Proto-Oncogene Proteins c-akt
1
2024
440
0.180
 Why?
Topotecan
3
2026
17
0.170
 Why?
Adult
17
2026
40872
0.170
 Why?
Central Nervous System
1
2024
282
0.170
 Why?
Phosphatidylinositol 3-Kinases
1
2023
383
0.160
 Why?
Whole Genome Sequencing
1
2021
178
0.160
 Why?
Salvage Therapy
2
2019
165
0.160
 Why?
Necrosis
2
2019
244
0.160
 Why?
Receptor, IGF Type 1
2
2010
64
0.150
 Why?
Pyridazines
1
2020
57
0.150
 Why?
Lung Neoplasms
2
2023
2667
0.150
 Why?
Dexamethasone
2
2019
365
0.140
 Why?
Etoposide
3
2017
168
0.140
 Why?
Imidazoles
1
2020
247
0.140
 Why?
Combined Modality Therapy
2
2020
1270
0.130
 Why?
Taxoids
1
2018
114
0.130
 Why?
Lymphoma
1
2019
241
0.130
 Why?
B7-H1 Antigen
1
2019
244
0.130
 Why?
Heterocyclic Compounds
1
2017
23
0.130
 Why?
Induction Chemotherapy
1
2017
88
0.130
 Why?
Antineoplastic Agents, Phytogenic
1
2018
178
0.130
 Why?
Cetuximab
1
2017
111
0.120
 Why?
Incidence
1
2024
2933
0.120
 Why?
Glucocorticoids
2
2019
532
0.120
 Why?
Azacitidine
1
2017
157
0.120
 Why?
Cytarabine
3
2025
66
0.120
 Why?
Clinical Trials as Topic
3
2025
1062
0.120
 Why?
Hematopoietic Stem Cell Transplantation
1
2022
699
0.120
 Why?
Retrospective Studies
6
2026
17325
0.110
 Why?
Myelodysplastic Syndromes
1
2017
165
0.110
 Why?
Cyclophosphamide
2
2026
272
0.110
 Why?
Feasibility Studies
1
2019
1115
0.110
 Why?
Treatment Outcome
9
2025
11793
0.110
 Why?
Thyroxine
1
2014
67
0.100
 Why?
Hypothyroidism
1
2014
68
0.100
 Why?
Pilot Projects
1
2019
1897
0.100
 Why?
Melanoma
1
2019
761
0.090
 Why?
Arsenicals
1
2013
28
0.090
 Why?
Oxides
1
2013
47
0.090
 Why?
Protein-Tyrosine Kinases
2
2022
431
0.090
 Why?
Organoplatinum Compounds
1
2012
65
0.090
 Why?
Leucovorin
1
2012
98
0.090
 Why?
In Situ Hybridization, Fluorescence
2
2012
328
0.090
 Why?
DNA Methylation
1
2017
690
0.090
 Why?
Animals
4
2021
38097
0.090
 Why?
Consensus
2
2025
479
0.090
 Why?
Fluorouracil
1
2012
231
0.090
 Why?
Real-Time Polymerase Chain Reaction
1
2012
337
0.080
 Why?
Spinal Cord
1
2014
382
0.080
 Why?
Magnetic Resonance Imaging
3
2019
3915
0.080
 Why?
HL-60 Cells
1
2010
30
0.080
 Why?
Inhibitory Concentration 50
1
2010
91
0.080
 Why?
Oligonucleotide Array Sequence Analysis
1
2012
751
0.080
 Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2012
979
0.080
 Why?
Antimetabolites, Antineoplastic
1
2010
106
0.080
 Why?
Pyrazoles
2
2025
517
0.080
 Why?
Drug Synergism
1
2010
354
0.080
 Why?
Pons
1
2009
33
0.080
 Why?
Brain
2
2014
2969
0.070
 Why?
Methotrexate
1
2010
233
0.070
 Why?
Vascular Endothelial Growth Factor A
2
2009
552
0.070
 Why?
Polyethylene Glycols
1
2014
649
0.070
 Why?
Infant, Newborn
3
2022
6464
0.070
 Why?
Recurrence
2
2010
1139
0.070
 Why?
Molecular Targeted Therapy
2
2022
440
0.070
 Why?
Chemistry, Pharmaceutical
1
2008
112
0.070
 Why?
Doxorubicin
1
2010
403
0.070
 Why?
Drug Design
1
2008
175
0.070
 Why?
Acute Disease
1
2010
1036
0.060
 Why?
Cell Cycle
1
2010
598
0.060
 Why?
Cell Survival
1
2010
1103
0.060
 Why?
Pyrimidines
2
2023
530
0.060
 Why?
MAP Kinase Signaling System
1
2008
308
0.060
 Why?
Genomics
2
2022
830
0.060
 Why?
Injections, Spinal
1
2026
120
0.060
 Why?
Risk Assessment
1
2015
3752
0.060
 Why?
Cohort Studies
3
2022
6032
0.060
 Why?
Everolimus
1
2025
112
0.050
 Why?
Proto-Oncogene Protein c-fli-1
1
2024
30
0.050
 Why?
RNA-Binding Protein EWS
1
2024
31
0.050
 Why?
Disease Progression
1
2012
2865
0.050
 Why?
United States Food and Drug Administration
1
2025
208
0.050
 Why?
Phenylurea Compounds
1
2025
119
0.050
 Why?
Europe
1
2025
421
0.050
 Why?
RNA, Messenger
1
2012
2805
0.050
 Why?
Mice
1
2021
18355
0.050
 Why?
Immunoconjugates
1
2025
138
0.050
 Why?
Quinolines
1
2025
190
0.050
 Why?
Vincristine
1
2024
144
0.050
 Why?
Lactams
1
2023
28
0.050
 Why?
Radioisotopes
1
2023
37
0.050
 Why?
Infusions, Intravenous
1
2024
428
0.050
 Why?
Cell Proliferation
1
2010
2514
0.050
 Why?
Lactams, Macrocyclic
1
2023
51
0.050
 Why?
Magnesium
1
2023
157
0.050
 Why?
Gene Amplification
1
2023
118
0.050
 Why?
National Cancer Institute (U.S.)
1
2022
54
0.050
 Why?
Aminopyridines
1
2023
129
0.050
 Why?
Oncogenes
1
2022
118
0.040
 Why?
Apoptosis
1
2010
2443
0.040
 Why?
Proto-Oncogene Proteins c-myc
1
2023
169
0.040
 Why?
Microtubule-Associated Proteins
1
2022
194
0.040
 Why?
Models, Biological
1
2008
1764
0.040
 Why?
Drug and Narcotic Control
1
2020
24
0.040
 Why?
Carcinogenesis
1
2022
228
0.040
 Why?
Drug Evaluation, Preclinical
1
2020
196
0.040
 Why?
Immunologic Factors
1
2022
260
0.040
 Why?
United States
3
2025
16123
0.040
 Why?
Fatigue
1
2022
365
0.040
 Why?
Proto-Oncogene Proteins
1
2022
625
0.040
 Why?
Base Sequence
1
2022
2171
0.040
 Why?
Disease Susceptibility
1
2020
344
0.040
 Why?
Retreatment
1
2018
80
0.030
 Why?
Isotretinoin
1
2018
26
0.030
 Why?
Metabolic Clearance Rate
1
2018
115
0.030
 Why?
Hematologic Diseases
1
2018
66
0.030
 Why?
Daunorubicin
1
2017
25
0.030
 Why?
Azepines
1
2018
105
0.030
 Why?
Precision Medicine
1
2021
461
0.030
 Why?
Benzylamines
1
2017
44
0.030
 Why?
Blepharoptosis
1
1997
13
0.030
 Why?
Genes, Dominant
1
1997
100
0.030
 Why?
Treatment Failure
1
2018
360
0.030
 Why?
Disease-Free Survival
1
2019
770
0.030
 Why?
Immunotherapy
1
2022
667
0.030
 Why?
Chromosomes, Human, Pair 1
1
1997
80
0.030
 Why?
Drug Hypersensitivity
1
2018
90
0.030
 Why?
Receptors, CXCR4
1
2017
91
0.030
 Why?
Gastrointestinal Diseases
1
2018
222
0.030
 Why?
Kaplan-Meier Estimate
1
2018
971
0.030
 Why?
Antibiotics, Antineoplastic
1
2016
140
0.030
 Why?
Drug Monitoring
1
2018
401
0.030
 Why?
SEER Program
1
2015
230
0.030
 Why?
Age Factors
1
2020
3346
0.020
 Why?
Genetic Predisposition to Disease
1
2021
2399
0.020
 Why?
Promoter Regions, Genetic
1
2017
1247
0.020
 Why?
Epigenesis, Genetic
1
2017
693
0.020
 Why?
Analysis of Variance
1
2015
1300
0.020
 Why?
Neoplasm Grading
1
2013
311
0.020
 Why?
Prevalence
1
2019
2874
0.020
 Why?
Mutation
1
2023
4090
0.020
 Why?
Radiography
1
2014
853
0.020
 Why?
Signal Transduction
1
2024
5223
0.020
 Why?
Prospective Studies
1
2022
8075
0.020
 Why?
Fatal Outcome
1
2009
305
0.020
 Why?
Tomography, X-Ray Computed
1
2018
2770
0.020
 Why?
Radiosurgery
1
2009
399
0.010
 Why?
Aged
1
2024
26215
0.010
 Why?
Middle Aged
1
2024
36302
0.010
 Why?
Lod Score
1
1997
62
0.010
 Why?
Quality of Life
1
2009
3210
0.010
 Why?
Genetic Markers
1
1997
338
0.010
 Why?
Recombination, Genetic
1
1997
205
0.010
 Why?
Chromosome Mapping
1
1997
507
0.010
 Why?
Pedigree
1
1997
515
0.010
 Why?
Genotype
1
1997
1857
0.010
 Why?
Macy's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (237) concept(s)
_
Co-Authors Expand Description
See all (19) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)